Cargando…

Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab

We hypothesized whether the reduction in eosinophilic airway inflammation in patients with chronic obstructive pulmonary disease (COPD) following treatment with benralizumab, a humanized, afucosylated, monoclonal antibody that binds to interleukin-5 receptor α, increases the airway bacterial load. A...

Descripción completa

Detalles Bibliográficos
Autores principales:	George, Leena, Wright, Adam, Mistry, Vijay, Sutcliffe, Amanda, Chachi, Latifa, Haldar, Koirobi, Ramsheh, Mohammadali Yavari, Richardson, Matthew, van der Merwe, René, Martin, Ubaldo, Newbold, Paul, Brightling, Christopher E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559763/ https://www.ncbi.nlm.nih.gov/pubmed/31239655 http://dx.doi.org/10.2147/COPD.S198302

Ejemplares similares

Microbiome balance in sputum determined by PCR stratifies COPD exacerbations and shows potential for selective use of antibiotics
por: Haldar, Koirobi, et al.
Publicado: (2017)

The sputum microbiome is distinct between COPD and health, independent of smoking history
por: Haldar, Koirobi, et al.
Publicado: (2020)

Sputum Moraxella catarrhalis strains exhibit diversity within and between COPD subjects
por: George, Leena M, et al.
Publicado: (2018)

Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a Haemophilus‐predominant subgroup
por: Diver, Sarah, et al.
Publicado: (2019)

Investigating the role of pentraxin 3 as a biomarker for bacterial infection in subjects with COPD
por: Thulborn, Samantha J, et al.
Publicado: (2017)

Face mask sampling reveals antimicrobial resistance genes in exhaled aerosols from patients with chronic obstructive pulmonary disease and healthy volunteers
por: Kennedy, Matthew, et al.
Publicado: (2018)

Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function
por: Bafadhel, Mona, et al.
Publicado: (2015)

Granulocyte–macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD
por: Saha, S, et al.
Publicado: (2009)

Inflammatory Endotype–associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis
por: Wang, Zhang, et al.
Publicado: (2021)

Blood and sputum eosinophils in COPD; relationship with bacterial load
por: Kolsum, Umme, et al.
Publicado: (2017)

Association Between Pathogens Detected Using Quantitative Polymerase Chain Reaction With Airway Inflammation in COPD at Stable State and Exacerbations
por: Barker, Bethan L., et al.
Publicado: (2015)

Detection of Cell-Dissociated Non-Typeable Haemophilus influenzae in the Airways of Patients with Chronic Obstructive Pulmonary Disease
por: Thulborn, Samantha J, et al.
Publicado: (2020)

Interleukin‐18, IL‐18 binding protein and IL‐18 receptor expression in asthma: a hypothesis showing IL‐18 promotes epithelial cell differentiation
por: Kaur, Davinder, et al.
Publicado: (2021)

Sputum microbiome profiling in COPD: beyond singular pathogen detection
por: Ditz, Benedikt, et al.
Publicado: (2020)

Bacteria and sputum inflammatory cell counts; a COPD cohort analysis
por: Beech, Augusta S., et al.
Publicado: (2020)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
por: Menzies-Gow, Andrew, et al.
Publicado: (2019)

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
por: Jackson, David J., et al.
Publicado: (2020)

Systemic and pulmonary inflammation is independent of skeletal muscle changes in patients with chronic obstructive pulmonary disease
por: Barker, Bethan L, et al.
Publicado: (2014)

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma
por: FitzGerald, J Mark, et al.
Publicado: (2019)

Profiling of Sputum Inflammatory Mediators in Asthma and Chronic Obstructive Pulmonary Disease
por: Bafadhel, M., et al.
Publicado: (2012)

Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases
por: Sridhar, Sriram, et al.
Publicado: (2019)

Neutrophil elastase as a biomarker for bacterial infection in COPD
por: Thulborn, Samantha J., et al.
Publicado: (2019)

NADPH Oxidase-4 Overexpression Is Associated With Epithelial Ciliary Dysfunction in Neutrophilic Asthma
por: Wan, Wing-Yan Heidi, et al.
Publicado: (2016)

Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity
por: Dagher, Rania, et al.
Publicado: (2022)

Fibrocyte localisation to the ASM bundle in asthma: bidirectional effects on cell phenotype and behaviour
por: Saunders, Ruth, et al.
Publicado: (2020)

Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction – PROMISE
por: Schleich, Florence, et al.
Publicado: (2023)

Sputum microbiology predicts health status in COPD
por: Braeken, Dionne CW, et al.
Publicado: (2016)

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
por: Bleecker, Eugene R., et al.
Publicado: (2018)

Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial Results
por: Ferguson, Gary T, et al.
Publicado: (2019)

Successful treatment of eosinophilic cystitis with benralizumab
por: Cooke, W Donald, et al.
Publicado: (2020)

Eosinophilic bronchiolitis successfully treated with benralizumab
por: Sugino, Keishi, et al.
Publicado: (2021)

Sputum cell count: biomarkers in the differentiation of asthma, COPD and asthma–COPD overlap
por: Gao, Jie, et al.
Publicado: (2017)

Characterization of sputum biomarkers for asthma–COPD overlap syndrome
por: Gao, Jing, et al.
Publicado: (2016)

The sputum transcriptome better predicts COPD exacerbations after the withdrawal of inhaled corticosteroids than sputum eosinophils
por: Ditz, Benedikt, et al.
Publicado: (2021)

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma
por: Emson, Claire, et al.
Publicado: (2020)

Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia
por: Isomoto, Kohsuke, et al.
Publicado: (2020)

Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
por: Singh, Dave, et al.
Publicado: (2023)

Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study
por: Menzies-Gow, Andrew, et al.
Publicado: (2022)

Dyspnea assessment and adverse events during sputum induction in COPD
por: Makris, Demosthenes, et al.
Publicado: (2006)

Glutathione S-transferase omega in the lung and sputum supernatants of COPD patients
por: Harju, Terttu H, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_p6moodiik6hvla63gpirgc1uvn